Cart
sales@molnova.com
Aducanumab
CAS No. 1384260-65-4
Aducanumab( —— )
Catalog No. M36802 CAS No. 1384260-65-4
Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brain permeability and may be used to treat Alzheimer's disease (AD).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 454 | In Stock |
|
| 10MG | 772 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAducanumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brain permeability and may be used to treat Alzheimer's disease (AD).
-
DescriptionAducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.
-
In Vitro——
-
In VivoAnimal Model:9.5- to 15.5-month-old Tg2576 transgenic mice Dosage:0.3-30 mg/kg Administration:Intraperitoneal injection (i.p.), weekly, 6 months Result: Increased recruitment of Iba-1-positive microglia to Aβ plaques.Animal Model:18-month-old Tg2576 mice Dosage:10 mg/kg Administration:Intraperitoneal injection (i.p.), weekly, 6 months Result:Restored neurite baseline calcium to control levels.Decreased the number of neurites with elevated levels of calcium after 2 weeks.Decreased the percentage of cell bodies with calcium overload.Restored the levels of VILIP and SERCA to control levels.Increased the cell numbers of NR1 and NR2A.Animal Model:22-month-old transgenic Tg2576 mice Dosage:0.4-1 mg/mL Administration: Intracerebroventricular injection (ICV), 20 minResult:Decreased the number of amyloid plaque.Decreased the size of the remaining individual plaques.Reduced amyloid plaque burden.
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetBeta Amyloid
-
RecptorBeta Amyloid
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1384260-65-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sevigny J, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016 Sep 1;537(7618):50-6. ?
molnova catalog
related products
-
β-Amyloid 1-16
β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
-
Amyloid β-peptide (1...
Rat form of the beta-Amyloid (1-40) peptide.
-
RAGE antagonist pept...
Receptor for advanced glycation end products (RAGE) antagonist. Blocks S100P, S100A4 and HMGB-1 mediated RAGE activation in vitro and in vivo. Inhibits growth and metastasis of rat glioma tumors. Reduces cell growth and RAGE-mediated NF-κB activity in human PDAC cell lines. Inhibits effects of TDI exposure in BALB/c mice.
